RSY-248
Gut inflammation
Phase 2Active
Key Facts
About Rasayana Therapeutics
Rasayana Therapeutics is a private, pre-revenue biotech founded in 2018 and based in San Diego, CA. The company is advancing a first-in-class, oral biologic platform focused on the gut mucosal interface, with a lead candidate, RSY-248, currently in Phase 2 development for gut inflammation. Rasayana's core thesis is that unresolved gut inflammation is a common driver of chronic conditions like IBD, metabolic disease, and autoimmunity, and that restoring evolutionary conserved biology like IAP can enable more durable disease control. The company is built for speed and impact, aiming to transform chronic disease treatment by targeting the origin of inflammation rather than its downstream symptoms.
View full company profile